Navigation Links
Aviir Laboratories Announce National Agreement With MultiPlan
Date:4/25/2012

IRVINE, Calif., April 25, 2012 /PRNewswire/ -- Aviir Diagnostic Laboratory announced today that it has entered into a contractual agreement with MultiPlan, Inc. for ancillary diagnostics laboratory testing. The agreement includes Aviir's participation in the MultiPlan, PHCS and PHCS Savility Networks.

Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients who are truly at high risk for the development of a cardiac event. Aviir's proprietary MiRisk™ and TruRisk™ assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years. Aviir's CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomics and genetic tests. www.aviir.com

Aviir's agreement with MultiPlan will give MultiPlan's participating providers and its clients' members access to Aviir's tests. Approximately 900,000 providers participate in MultiPlan's provider networks and an estimated 57 million consumers have access to one or more of these networks.

"There is currently a significant yet unmet clinical need in the medical community for more effective ways to identify individuals at high risk of a heart attack who are missed by current evaluation methods. Providing an accurate assessment of the patient's overall heart health is the first step in prevention of cardiovascular disease," stated Douglas Harrington, M.D., Chief Executive Officer of Aviir. "Our agreement with MultiPlan will help ensure more doctors and therefore patients have access to the tools that can provide the accurate assessment."

"At Aviir, our ultimate goal is to help physicians identify those patients who are at serious risk of experiencing a heart attack but are completely unaware of their precarious condition. Armed with better information, physicians will be able to customize individualized treatment plans with the goal of improving patient therapeutic compliance, reduce their risk of heart attacks, and decrease the overall cost of care." Dr. Harrington added.

Learn more about Aviir at www.aviir.com.

Learn more about MultiPlan at www.multiplan.com.

For more information:
Dina Scaglione
(949) 910-9401
dina.scaglione@aviir.com


'/>"/>
SOURCE Aviir Diagnostic Laboratory
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Aviir Diagnostics Laboratory in Collaboration with Cause;ology Sponsors "Storyland," a Red Carpet Charity Extravaganza in Hollywood
2. MO BIO Laboratories, Inc. Launches the PowerMicrobiome™ RNA Isolation Kit
3. ARUP Laboratories Announces Creation of Business Innovations Division
4. EMD Millipore Partners with Charles River Laboratories for Improved Viral Clearance Studies
5. John Saltamartine to Lead Operations as VR Laboratories Chief Operating Officer
6. ARUP Laboratories Pathologist, Ronald L. Weiss, MD, Honored With Lifetime Achievement Award for Contributions to Patient Care and Pathology
7. IDEXX Laboratories Acquires the RADIL Reference Laboratory from the University of Missouri
8. VetNostic Laboratories® Announces New Testing for Dog Breeds
9. Access Medical Laboratories, Inc. to Celebrate Grand Opening of New Laboratory Headquarters in Jupiter, Florida
10. Building, Validating & Maintaining Controlled Environment Facilities is Focus of Oct. 18th Seminar in Boston Hosted by Microtest Laboratories
11. MO BIO Laboratories, Inc. Launches the RTS DNase™ Kit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017   Biostage, Inc. (Nasdaq: ... developing bioengineered organ implants to treat cancers and other ... today the closing on February 15, 2017 of its ... stock and warrants to purchase 20,000,000 shares of common ... offering was priced at $0.40 per share of common ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... Dr. Kingsley Chin, professor and Harvard trained surgeon, completed the procedure on Monday, ... on a 55-year-old practicing female physician suffering from degenerative disc disease with radiculomyelopathy, ...
(Date:2/15/2017)... ... , ... Executive search firm, Slone Partners, announces the placement ... is a veteran life sciences and molecular diagnostics executive with extensive commercialization experience. ... disease risk in future generations. In his new role, Matt will be responsible ...
(Date:2/15/2017)... WARRINGTON, Pa. , Feb. 15, 2017 /PRNewswire/ ... ), a biotechnology company focused on developing aerosolized ... that it has completed a $10.5 million private ... expects that it has sufficient capital to fund ... 2b clinical trial data release in mid-2017. ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
Breaking Biology News(10 mins):